On September 15, 2021, Celcuity, a company listed on the NASDAQ under the ticker symbol CELC, submitted a Form 8-K to the U.S. Securities and Exchange Commission (SEC). The filing disclosed a change in its Board of Directors.
The document reveals that on September 14, 2021, Celcuity's Board of Directors accepted the resignation of John J. Shannon, Jr. Mr. Shannon served as a member of the Board and its Audit Committee. The resignation became effective on September 14, 2021. Following Mr. Shannon's departure, the Board of Directors size was reduced to five members.
Although the filing did not provide detailed reasons for Mr. Shannon's resignation, it marks a notable change within the company's governing body. Such alterations in the leadership structure can impact a company's operations and strategic decision-making.
Investors and stakeholders in Celcuity NASDAQ: CELC may closely monitor any further developments related to the Board of Directors and its composition, as changes at this level can signal shifts in corporate governance and management direction. Celcuity's stock performance and overall corporate trajectory may also be influenced by these dynamics in the near future.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Celcuity's 8K filing here.
About Celcuity
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
